These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7534917)

  • 1. Inhibition of androgen synthesis by 22-hydroximino-23,24-bisnor-4-cholen-3-one.
    Li J; Li Y; Son C; Brodie AM
    Prostate; 1995 Mar; 26(3):140-50. PubMed ID: 7534917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
    Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
    Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.
    Hartmann RW; Hector M; Haidar S; Ehmer PB; Reichert W; Jose J
    J Med Chem; 2000 Nov; 43(22):4266-77. PubMed ID: 11063622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-pregnene-3-one-20 beta-carboxaldehyde: a potent inhibitor of 17 alpha-hydroxylase/C17,20-lyase and of 5 alpha-reductase.
    Li J; Li Y; Son C; Banks P; Brodie A
    J Steroid Biochem Mol Biol; 1992 May; 42(3-4):313-20. PubMed ID: 1606043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
    Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
    Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo.
    Nnane IP; Njar VC; Liu Y; Lu Q; Brodie AM
    J Steroid Biochem Mol Biol; 1999 Dec; 71(3-4):145-52. PubMed ID: 10659703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
    Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in vitro activity of some epimeric 20 alpha-hydroxy, 20-oxime and aziridine pregnene derivatives as inhibitors of human 17 alpha-hydroxylase/C17,20-lyase and 5 alpha-reductase.
    Ling YZ; Li JS; Kato K; Liu Y; Wang X; Klus GT; Marat K; Nnane IP; Brodie AM
    Bioorg Med Chem; 1998 Oct; 6(10):1683-93. PubMed ID: 9839000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
    Nnane IP; Long BJ; Ling YZ; Grigoryev DN; Brodie AM
    Br J Cancer; 2000 Jul; 83(1):74-82. PubMed ID: 10883671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY207320 (6-methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5 alpha-reductase, and produces prostatic regression in male rats.
    Neubauer BL; Best KL; Blohm TR; Gates C; Goode RL; Hirsch KS; Laughlin ME; Petrow V; Smalstig EB; Stamm NB
    Prostate; 1993; 23(3):181-99. PubMed ID: 8234065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
    Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
    J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute immobilization stress disrupts testicular steroidogenesis in adult male rats by inhibiting the activities of 17 alpha-hydroxylase and 17,20-lyase without affecting the binding of LH/hCG receptors.
    Orr TE; Taylor MF; Bhattacharyya AK; Collins DC; Mann DR
    J Androl; 1994; 15(4):302-8. PubMed ID: 7982797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats.
    Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Yoden T; Okada M; Fujikura T; Akaza H; Shikama H
    Prostate; 1998 Sep; 37(1):10-8. PubMed ID: 9721064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of steroid 5alpha-reductase inhibitor ONO-9302 and anti-androgen allylestrenol on the prostatic growth, and plasma and prostatic hormone levels in rats.
    Yasuda N; Fujino K; Shiraji T; Nambu F; Kondo K
    Jpn J Pharmacol; 1997 Jul; 74(3):243-52. PubMed ID: 9268084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo.
    Haidar S; Ehmer PB; Barassin S; Batzl-Hartmann C; Hartmann RW
    J Steroid Biochem Mol Biol; 2003 Apr; 84(5):555-62. PubMed ID: 12767280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-reductase inhibitor ONO-3805.
    Nagamoto A; Noguchi K; Murai T; Kinoshita Y
    J Androl; 1994; 15(6):521-7. PubMed ID: 7721654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells.
    Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Fujikura T; Akaza H; Shikama H
    Jpn J Pharmacol; 1999 Feb; 79(2):213-20. PubMed ID: 10202857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17 alpha-hydroxylase/C17,20-lyase.
    Li JS; Li Y; Son C; Brodie AM
    J Med Chem; 1996 Oct; 39(21):4335-9. PubMed ID: 8863811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
    Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
    Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.